Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
|ClinicalTrials.gov Identifier: NCT02258217|
Recruitment Status : Completed
First Posted : October 7, 2014
Last Update Posted : September 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Relapsing Remitting Multiple Sclerosis||Drug: Acthar||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||June 24, 2016|
|Actual Study Completion Date :||December 2016|
Experimental: Single arm
Acthar 80 units subcutaneously for five consecutive days.
Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
Other Name: repository corticotropin
- ARMS (assessing relapses in multiple sclerosis) [ Time Frame: baseline visit ]Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit.
- GASE scale questionnaire (generic assessment of side effects) [ Time Frame: 1 week ]Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02258217
|United States, Ohio|
|Columbus, Ohio, United States, 43214|
|Principal Investigator:||Aaron L Boster, MD||OhioHealth|